Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Oncology Hematology Care Inc-Healthplex
mi
from
Fairfield, OH
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Oncology Hematology Care Inc-Healthplex
mi
from
Fairfield, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Warren Clinic Oncology-Tulsa
mi
from
Tulsa, OK
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Warren Clinic Oncology-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Geisinger Medical Oncology-Lewisburg
mi
from
Lewisburg, PA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Geisinger Medical Oncology-Lewisburg
mi
from
Lewisburg, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Pali Momi Medical Center
mi
from
'Aiea, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Pali Momi Medical Center
mi
from
'Aiea, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Cancer Care Inc-POB II
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Cancer Care Inc-POB II
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Cancer Care Inc-Liliha
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Cancer Care Inc-Liliha
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Oncology Inc-Kuakini
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Oncology Inc-Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Reid Health
mi
from
Richmond, IN
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Frontier Cancer Center
mi
from
Billings, MT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Commack
mi
from
Commack, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Sleepy Hollow
mi
from
Sleepy Hollow, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Sleepy Hollow
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Sanford Broadway Medical Center
mi
from
Fargo, ND
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Sanford Broadway Medical Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
MedStar Washington Hospital Center
mi
from
Washington,
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Click here to add this to my saved trials
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Click here to add this to my saved trials
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Biobehavioral Intervention in Gynecologic Oncology Patients
Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation
Status: Enrolling
Updated:  12/4/2017
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Biobehavioral Intervention in Gynecologic Oncology Patients
Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation
Status: Enrolling
Updated: 12/4/2017
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Status: Enrolling
Updated:  12/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Status: Enrolling
Updated: 12/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
A Phase II Study of the Synergistic Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Status: Enrolling
Updated:  12/5/2017
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
A Phase II Study of the Synergistic Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Status: Enrolling
Updated: 12/5/2017
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Miami Children's Hospital
mi
from
Miami, FL
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Kosair Children's Hospital
mi
from
Louisville, KY
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Hurley Medical Center
mi
from
Flint, MI
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials